Kilitch Drugs (India) Past Earnings Performance
Past criteria checks 3/6
Kilitch Drugs (India) has been growing earnings at an average annual rate of 46.6%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 24.3% per year. Kilitch Drugs (India)'s return on equity is 7.5%, and it has net margins of 10.4%.
Key information
46.6%
Earnings growth rate
46.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 24.3% |
| Return on equity | 7.5% |
| Net Margin | 10.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kilitch Drugs (India) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,575 | 165 | 281 | 0 |
| 30 Jun 24 | 1,513 | 126 | 252 | 0 |
| 31 Mar 24 | 1,544 | 146 | 240 | 0 |
| 31 Dec 23 | 1,550 | 146 | 243 | 0 |
| 30 Sep 23 | 1,532 | 140 | 240 | 0 |
| 30 Jun 23 | 1,427 | 117 | 238 | 0 |
| 31 Mar 23 | 1,396 | 104 | 232 | 0 |
| 31 Dec 22 | 1,307 | 98 | 178 | 0 |
| 30 Sep 22 | 1,352 | 85 | 154 | 0 |
| 30 Jun 22 | 1,281 | 83 | 133 | 0 |
| 31 Mar 22 | 1,142 | 74 | 117 | 0 |
| 31 Dec 21 | 976 | 52 | 132 | 0 |
| 30 Sep 21 | 835 | 63 | 126 | 0 |
| 30 Jun 21 | 780 | 62 | 110 | 0 |
| 31 Mar 21 | 685 | 37 | 97 | 0 |
| 31 Dec 20 | 602 | 17 | 89 | 0 |
| 30 Sep 20 | 558 | 4 | 91 | 0 |
| 30 Jun 20 | 531 | -3 | 92 | 0 |
| 31 Mar 20 | 533 | 8 | 114 | 0 |
| 31 Dec 19 | 609 | 26 | 103 | 0 |
| 30 Sep 19 | 534 | -32 | 111 | 0 |
| 30 Jun 19 | 648 | -3 | 127 | 0 |
| 31 Mar 19 | 825 | 38 | 159 | 0 |
| 31 Mar 18 | 510 | 52 | 77 | 0 |
| 31 Mar 17 | 287 | -89 | 172 | 0 |
| 31 Mar 16 | 210 | -112 | 155 | 0 |
| 31 Mar 15 | 190 | -3 | 129 | 0 |
| 31 Dec 14 | 222 | -8 | 94 | 0 |
| 30 Sep 14 | 199 | 8 | 97 | 0 |
| 30 Jun 14 | 168 | -1 | 93 | 0 |
| 31 Mar 14 | 149 | 12 | 87 | 0 |
| 31 Dec 13 | 151 | 35 | 51 | 0 |
Quality Earnings: 524500 has high quality earnings.
Growing Profit Margin: 524500's current net profit margins (10.4%) are higher than last year (9.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524500 has become profitable over the past 5 years, growing earnings by 46.6% per year.
Accelerating Growth: 524500's earnings growth over the past year (17.3%) is below its 5-year average (46.6% per year).
Earnings vs Industry: 524500 earnings growth over the past year (17.3%) did not outperform the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 524500's Return on Equity (7.5%) is considered low.